Understanding and Preventing Recurring Bacterial Vaginosis: Important Considerations for Clinicians

References

• Peebles K, Velloza J, Balkus JE, McClelland RS, Barnabas RV. High global burden and costs of bacterial vaginosis: a systematic review and meta-analysis. Sex Transm Dis. 2019;46(5):304–311. doi:10.1097/OLQ.0000000000000972
   PubMed Web of Science ®Google Scholar
• Cohen CR, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 2012;9(6):e1001251. doi:10.1371/journal.pmed.1001251
   PubMed Web of Science ®Google Scholar
• Brotman RM, Klebanoff MA, Nansel TR, et al. Bacterial vaginosis assessed by gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J Infect Dis. 2010;202(12):1907–1915. doi:10.1086/657320
   PubMed Web of Science ®Google Scholar
• Ness RB, Kip KE, Hillier SL, et al. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol. 2005;162(6):585–590. doi:10.1093/aje/kwi243
   PubMed Web of Science ®Google Scholar
• Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med. 1995;333(26):1737–1742. doi:10.1056/NEJM199512283332604
   PubMed Web of Science ®Google Scholar
• Leitich H, Bodner-Adler B, Brunbauer M, Kaider A, Egarter C, Husslein P. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol. 2003;189(1):139–147. doi:10.1067/mob.2003.339
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Muzny CA, Josey WE. Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis: a conceptual model. J Infect Dis. 2014;210(3):338–343. doi:10.1093/infdis/jiu089
   PubMed Web of Science ®Google Scholar
• Hickey RJ, Forney LJ. Gardnerella vaginalis does not always cause bacterial vaginosis. J Infect Dis. 2014;210(10):1682–1683. doi:10.1093/infdis/jiu303
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Muzny CA, Josey WE. Reply to Hickey and Forney. J Infect Dis. 2014;210(10):1683–1684. doi:10.1093/infdis/jiu304
   PubMedGoogle Scholar
• Muzny CA, Taylor CM, Swords WE, et al. An updated conceptual model on the pathogenesis of bacterial vaginosis. J Infect Dis. 2019;220(9):1399–1405. doi:10.1093/infdis/jiz342
   PubMed Web of Science ®Google Scholar
• Muzny CA, Schwebke JR. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. J Infect Dis. 2016;214:S1–5. doi:10.1093/infdis/jiw121
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106(5 Pt 1):1013–1023. doi:10.1097/01.AOG.0000183594.45524.d2
   PubMed Web of Science ®Google Scholar
• Koumans EH, Markowitz LE, Hogan V, and CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis. 2002;35(Suppl 2):S152–172. doi:10.1086/342103
   PubMedGoogle Scholar
• Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478–1486. doi:10.1086/503780
   PubMed Web of Science ®Google Scholar
• Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194(5):1283–1289. doi:10.1016/j.ajog.2005.11.041
   PubMed Web of Science ®Google Scholar
• Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97 e91–96. doi:10.1016/j.ajog.2007.06.039
   Web of Science ®Google Scholar
• Muzny CA, Schwebke JR. Biofilms: an underappreciated mechanism of treatment failure and recurrence in vaginal infections. Clin Infect Dis. 2015;61(4):601–606. doi:10.1093/cid/civ353
   PubMed Web of Science ®Google Scholar
• Muzny CA, Sobel JD. The role of antimicrobial resistance in refractory and recurrent bacterial vaginosis and current recommendations for treatment. Antibiotics. 2022;11(4). doi:10.3390/antibiotics11040500
   Google Scholar
• Mitchell CM, Abbe CR. Bacterial vaginosis: a review of approaches to treatment and prevention. Front Reproductive Health. 2023;5:1100029. doi:10.3389/frph.2023.1100029
   PubMedGoogle Scholar
• Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29(2):297–301. doi:10.1128/jcm.29.2.297-301.1991
   PubMed Web of Science ®Google Scholar
• Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14–22. doi:10.1016/0002-9343(83)91112-9
   PubMed Web of Science ®Google Scholar
• Coudray MS, Madhivanan P. Bacterial vaginosis-A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2020;245:143–148. doi:10.1016/j.ejogrb.2019.12.035
   PubMed Web of Science ®Google Scholar
• Stewart LL, Vodstrcil LA, Coombe J, Bradshaw CS, Hocking JS. Prevalence of bacterial vaginosis in postmenopausal women: a systematic review and meta-analysis. Sex Health. 2022;19(1):17–26. doi:10.1071/SH21083
   PubMed Web of Science ®Google Scholar
• Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864–869. doi:10.1097/OLQ.0b013e318074e565
   PubMed Web of Science ®Google Scholar
• Muzny CA, Schwebke JR. Asymptomatic bacterial vaginosis: to treat or not to treat? Curr Infect Dis Rep. 2020;22(12). doi:10.1007/s11908-020-00740-z
   PubMed Web of Science ®Google Scholar
• Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. doi:10.15585/mmwr.rr7004a1
   PubMed Web of Science ®Google Scholar
• Subtil D, Brabant G, Tilloy E, et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet. 2018;392(10160):2171–2179. doi:10.1016/S0140-6736(18)31617-9
   PubMed Web of Science ®Google Scholar
• Odendaal HJ, Popov I, Schoeman J, Smith M, Grove D. Preterm labour--is bacterial vaginosis involved? S Afr Med J. 2002;92(3):231–234.
   PubMed Web of Science ®Google Scholar
• Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 2000;342(8):534–540. doi:10.1056/NEJM200002243420802
   PubMed Web of Science ®Google Scholar
• Vermeulen GM, Bruinse HW. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. Br J Obstet Gynaecol. 1999;106(7):652–657. doi:10.1111/j.1471-0528.1999.tb08363.x
   PubMedGoogle Scholar
• Li XD, Wang CC, Zhang XJ, et al. Risk factors for bacterial vaginosis: results from a cross-sectional study having a sample of 53,652 women. Eur J Clin Microbiol Infect Dis. 2014;33(9):1525–1532. doi:10.1007/s10096-014-2103-1
   PubMed Web of Science ®Google Scholar
• Peebles K, Kiweewa FM, Palanee-Phillips T, et al. Elevated risk of bacterial vaginosis among users of the copper intrauterine device: a prospective longitudinal cohort study. Clin Infect Dis. 2021;73(3):513–520. doi:10.1093/cid/ciaa703
   PubMed Web of Science ®Google Scholar
• Madden T, Grentzer JM, Secura GM, Allsworth JE, Peipert JF. Risk of bacterial vaginosis in users of the intrauterine device: a longitudinal study. Sex Transm Dis. 2012;39(3):217–222. doi:10.1097/OLQ.0b013e31823e68fe
   PubMed Web of Science ®Google Scholar
• Hubacher D, Chen PL, Park S. Side effects from the copper IUD: do they decrease over time? Contraception. 2009;79(5):356–362. doi:10.1016/j.contraception.2008.11.012
   PubMed Web of Science ®Google Scholar
• Bradshaw CS, Vodstrcil LA, Hocking JS, et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis. 2013;56(6):777–786. doi:10.1093/cid/cis1030
   PubMed Web of Science ®Google Scholar
• Zozaya M, Ferris MJ, Siren JD, et al. Bacterial communities in penile skin, male urethra, and vaginas of heterosexual couples with and without bacterial vaginosis. Microbiome. 2016;4:16. doi:10.1186/s40168-016-0161-6
   PubMed Web of Science ®Google Scholar
• Liu CM, Hungate BA, Tobian AA, et al. Penile microbiota and female partner bacterial vaginosis in Rakai, Uganda. MBio. 2015;6(3):e00589. doi:10.1128/mBio.00589-15
   PubMed Web of Science ®Google Scholar
• Toh E, Xing Y, Gao X, et al. Sexual behavior shapes male genitourinary microbiome composition. Cell Rep Med. 2023;4(3):100981. doi:10.1016/j.xcrm.2023.100981
   PubMedGoogle Scholar
• Russo CL, Spurr-Michaud S, Tisdale A, Pudney J, Anderson D, Gipson IK. Mucin gene expression in human male urogenital tract epithelia. Hum Reprod. 2006;21(11):2783–2793. doi:10.1093/humrep/del164
   PubMed Web of Science ®Google Scholar
• Turner E, Sobel JD, Akins RA. Prognosis of recurrent bacterial vaginosis based on longitudinal changes in abundance of Lactobacillus and specific species of Gardnerella. PLoS One. 2021;16(8):e0256445. doi:10.1371/journal.pone.0256445
   PubMed Web of Science ®Google Scholar
• Muzny CA, Balkus J, Mitchell C, et al. Diagnosis and Management of Bacterial Vaginosis: summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clin Infect Dis. 2022;74(Suppl_2):S144–S151. doi:10.1093/cid/ciac021
   PubMed Web of Science ®Google Scholar
• Muzny CA, Cerca N, Elnaggar JH, Taylor CM, Sobel JD, Van Der Pol B. State of the art for diagnosis of bacterial vaginosis. J Clin Microbiol. 2023;e0083722. doi:10.1128/jcm.00837-22
   PubMed Web of Science ®Google Scholar
• Sobel JD, Kaur N, Woznicki NA, et al. Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses. Infect Drug Resist. 2019;12:2297–2307. doi:10.2147/IDR.S213853
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Lensing SY, Lee J, et al. Treatment of male sexual partners of women with bacterial vaginosis: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2021;73(3):e672–e679. doi:10.1093/cid/ciaa1903
   PubMed Web of Science ®Google Scholar
• Mehta SD. Systematic review of randomized trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sex Transm Dis. 2012;39(10):822–830. doi:10.1097/OLQ.0b013e3182631d89
   PubMed Web of Science ®Google Scholar
• Vodstrcil LA, Hocking JS, Law M, et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta-analysis. PLoS One. 2013;8(9):e73055. doi:10.1371/journal.pone.0073055
   PubMed Web of Science ®Google Scholar
• Vodstrcil LA, Plummer ME, Fairley CK, et al. Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. Sci Rep. 2019;9(1):3555. doi:10.1038/s41598-019-39879-8
   PubMedGoogle Scholar
• Brotman RM, He X, Gajer P, et al. Association between cigarette smoking and the vaginal microbiota: a pilot study. BMC Infect Dis. 2014;14:471. doi:10.1186/1471-2334-14-471
   PubMed Web of Science ®Google Scholar
• Surapaneni S, Akins R, Sobel JD. Recurrent bacterial vaginosis: an unmet therapeutic challenge. experience with a combination pharmacotherapy long-term suppressive regimen. Sex Transm Dis. 2021;48(10):761–765. doi:10.1097/OLQ.0000000000001420
   PubMed Web of Science ®Google Scholar
• Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Transm Dis. 2009;36(11):732–734. doi:10.1097/OLQ.0b013e3181b08456
   PubMed Web of Science ®Google Scholar
• Marrazzo JM, Dombrowski JC, Wierzbicki MR, et al. Safety and efficacy of a novel vaginal anti-infective, Tol-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: a randomized, single-blind, phase 2, controlled trial. Clin Infect Dis. 2019;68(5):803–809. doi:10.1093/cid/ciy554
   PubMed Web of Science ®Google Scholar
• Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353(18):1899–1911. doi:10.1056/NEJMoa043802
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Woody J, Hunt C, Budd W. Antimicrobial resistance genes and modelling of treatment failure in bacterial vaginosis: clinical study of 289 symptomatic women. J Med Microbiol. 2016;65(5):377–386. doi:10.1099/jmm.0.000236
   PubMedGoogle Scholar
• Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK. Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol. 2004;191(6):1898–1906. doi:10.1016/j.ajog.2004.06.089
   PubMed Web of Science ®Google Scholar
• Aguin TJ, Akins RA, Sobel JD. High-dose vaginal metronidazole for recurrent bacterial vaginosis--a pilot study. J Low Genit Tract Dis. 2014;18(2):156–161. doi:10.1097/LGT.0b013e31829a5558
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. 2007;44(2):213–219. doi:10.1086/509577
   PubMed Web of Science ®Google Scholar
• Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009;1(4):CD006289.
   Google Scholar
• Cohen CR, Wierzbicki MR, French AL, et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2020;382(20):1906–1915. doi:10.1056/NEJMoa1915254
   PubMed Web of Science ®Google Scholar
• Lev-Sagie A, Goldman-Wohl D, Cohen Y, et al. Vaginal microbiome transplantation in women with intractable bacterial vaginosis. Nat Med. 2019;25(10):1500–1504. doi:10.1038/s41591-019-0600-6
   PubMed Web of Science ®Google Scholar
• Mollin A, Katta M, Sobel JD, Akins RA. Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes. PLoS One. 2022;17(7):e0272012. doi:10.1371/journal.pone.0272012
   PubMed Web of Science ®Google Scholar
• Swidsinski S, Moll WM, Swidsinski A. Bacterial Vaginosis-Vaginal Polymicrobial Biofilms and Dysbiosis. Dtsch Arztebl Int. 2023;120(20):347–354. doi:10.3238/arztebl.m2023.0090
   PubMed Web of Science ®Google Scholar